IP Library Granted Patent US 7,888,369
Granted Patent B2
US 7,888,369 · App. 11/642,170 · Granted Feb 15, 2011

Oxazoloisoquinoline derivatives as thrombin receptor antagonists

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 7,888,369
App. No.
11/642,170
Granted
Feb 15, 2011
Kind
B2
Abstract

This application provides for oxazolisoquinoline derivatives of the formula or a pharmaceutically acceptable salt of said compound wherein: B is —CH═CH—; M is —C(R 1 )(R 2 )—; and the remaining substituents are as defined in the specification as well as pharmaceutical compositions containing them and a method of treating diseases associated with thrombosis, atherosclerosis, restenosis, hypertension, angina pectoris, arrhythmia, heart failure, and cancer by administering said compounds. This application also provides for combination therapy with the compounds of Ib or pharmaceutically acceptable salts thereof with other cardiovascular agents.

Claims (23)

1. A compound of the formula

or a pharmaceutically acceptable salt of said compound wherein:

B is —CH═CH—;

M is —C(R 1 )(R 2 )—;

n is 0 or 1;

Het is a mono heteroaromatic group of 5 to 6 atoms comprised of 2 to 5 carbon atoms and 1 to 2 heteroatoms independently selected from the group consisting of N, O and S, with the proviso that there are no adjacent oxygen or sulfur atoms present in the heteroaromatic group, wherein a ring nitrogen can form an N-oxide or a quaternary group with an alkyl group, wherein Het is attached to B by a carbon atom ring member of the Het group, and wherein the Het group is substituted by 1 moiety, W,

wherein W is aryl or aryl substituted by 1 to 3 substituents independently selected from the group consisting of alkyl, halogen, -Oalkyl, —CN, —CF 3 , and —OH;

R 1 and R 2 are independently hydrogen or alkyl; and

Q is

wherein each R 13 and R14 are hydrogen.

2. A compound of claim 1 or a pharmaceutically acceptable salt thereof wherein said compound is of the formula:

3. A compound of claim 1 or a pharmaceutically acceptable salt thereof wherein:

Het is

W is

4. A compound of claim 1 or a pharmaceutically acceptable salt thereof wherein:

Het is

W is

5. A compound of selected from the group consisting of:

or pharmaceutically acceptable salt or thereof.

6. A compound of claim 1 which has the following formula:

or a pharmaceutically acceptable salt thereof.

7. A pharmaceutical composition comprising an effective amount of at least one compound of claim 1 or a pharmaceutically acceptable salt thereof and a pharmaceutically acceptable carrier.

8. A pharmaceutical composition comprising an effective amount of at least one compound of claim 5 or a pharmaceutically acceptable salt thereof and a pharmaceutical carrier.

Assignments (2)
MERGER Recorded Aug 8, 2022
From: MERCK SHARP & DOHME CORP.
To: MERCK SHARP & DOHME LLC
Reel/Frame 061102/0145 →
CHANGE OF NAME Recorded Aug 30, 2012
From: SCHERING CORPORATION
To: MERCK SHARP & DOHME CORP.
Reel/Frame 028884/0151 →